Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 432-690-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://chesar.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2004
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP study using standard method; large dosing factor
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 004
- Report date:
- 2004
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- other: Annex V
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Details on test material:
- yellow powder
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Ltd, UK
- Age at study initiation: 6 - 8 weeks
- Weight at study initiation: males: 185-232 g; females: 151-187 g
- Fasting period before study:
- Housing: groups of = 4 separated by sex, grid floor cages
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum):ad libitum
- Acclimation period: 14 d
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 +/-2 C
- Humidity (%): 55+/- 15 %
- Air changes (per hr): >15
- Photoperiod (hrs dark / hrs light): 12/12 h
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- Method of administration:
Gavage - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Method: HPLC with UV detection (350 nm)
Column: Luna 5µm C18 (250X4.6 mm id
Solvent A: acetonitrile
Solvent B: 0,1 M ammonium acetate in water with 1% acetonitrile
Gradient: 100 % B - 90% B in 16 minutes
Results:
Stability: Samples were stored for 14 days in the dark; 96 -100 % of initial levels were found
Homogeneity: triplicate determinations for all dose levels showed good homogeneity
Dosage/Concentration: Weekly determinations in samples of all dose levels gave measured concentrations of 94 -110 % of nominal values. - Duration of treatment / exposure:
- Test duration: 90 days
- Frequency of treatment:
- Daily
Dosing regime: 7 days/week
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
Low: 5 mg/kg bw/day
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
Medium: 50 mg/kg bw/day
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
High: 750 mg/kg bw per day ; reduced to 500 mg/kg bw/day on day 56 due to severe effects
Basis:
actual ingested
- No. of animals per sex per dose:
- Male: 10 animals
Female: 10 animals - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on a range finding study
- Rationale for animal assignment (if not random): random - Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes / No / No data
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: before start, then weekly
BODY WEIGHT: Yes
- Time schedule for examinations: day 0, then weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each cage group determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: daily inspection, no quantification
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: before start: control + high dose group; week 13 all treated animals
HAEMATOLOGY: Yes
- Time schedule for collection of blood: day 90
- Anaesthetic used for blood collection: No data
- Animals fasted: No
- How many animals: all survivors (day 90)
- Parameters checked: Hemoglobin, Erythrocyte count, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin(- concentration), total leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, reticulocytes, prothrombin time, activated partial thromboplastin time
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: day 90
- Animals fasted: No
- How many animals:all survivors (day 90)
- Parameters checked: Urea, Glucose, tot. protein, albumin, albumin/globulin ratio, sodium, potassium, calcium, chloride, inorg. phosphorus, ASAT, ALAT, Alk. phosphatase, creatinine, tot. cholesterol, tot. bilirubin
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: weeks 12 or 13
- Dose groups that were examined: all survivors
- Battery of functions tested: sensory activity / grip strength / motor activity - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, organ weights: Adrenals, brain, testes, epididymides, heart, kidneys, liver, ovaries, spleen, thymus, uterus
HISTOPATHOLOGY: Yes (see table)
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Mortailty: high dose : 3 females on days 28, 42, 53 and after dose reduction (day 56) on days 58 and 74. Two males were killed in extremis on days 85 and 89. Clinical signs: see below
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Mortailty: high dose : 3 females on days 28, 42, 53 and after dose reduction (day 56) on days 58 and 74. Two males were killed in extremis on days 85 and 89. Clinical signs: see below
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Male and females of the high dose group showed reduced body weight gain.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Reduced dietary intake was evident for animals of either sex treated at the high dose throughout the study. No adverse effects were detected for animals treated with 50 or 5 mg/kg/day.
- Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- Food efficiencies were similarly affected as food consumption.
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- high dose: males & females showed microcytic hypochromic anaemia. Males had reduced clotting time, elevated mean cell hemoglobin concentration and leukocyte count.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- see below
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- see below
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- see below
- Details on results:
- Clinical observations:
Following the deaths of three high dose females, the top dose level was reduced from 750 to 500 mg/kg/day from day 56. Further deaths occurred at this dose; two high dose females were found dead on days 58 and 74 and two high dose males were killed in extremis on days 85 and 89. No mortalities occurred at other dose levels. Clinically observable signs of hunched posture were detected for 750 mg/kg/day dosed animals and deterioration in physical condition was evident, resulting in four deaths and the subsequent reduction of the dose level to 500 mg/kg/day. The reduction in dose level did not result in a regression in clinical signs and pallor of the extremities was evident for all high dose animals until th end of the study, with hunched posture observed for individual animals. Bright yellow staining was detected on cage tray-liners of high dose females. Reduced bodyweight gains were observed for high dose males throughout the study and for high dose females during the first three weeks of the study and there was reduced dietary intake for all high dose animals. No treatment-related effects were observed for animals of either sex treated with 50 or 5 mg/kg/day.
Laboratory findings:
Haematology and blood chemistry: High dose animals displayed microcytic hypochromic anaemia. High dose males had a reduction in clotting time, elevated mean cell haemoglobin concentration and leucocyte count, particularly in the lymphocyte fraction. High dose animals showed reduced albumin concentration, with reduction in total protein evident for males only. High dose animals also showed elevated alanine aminotransferase and phosphorus levels. Furthermore aspartate aminotransferase levels were elevated for males only and high dose females showed an increase in sodium concentration. No such effects were observed for animals of either sex treated with 50 or 5 mg/kg/day.
Effects in organs:
High dose males showed a reduction in absolute weight for the majority of the organs, whereas high dose females showed reduced absolute spleen, thymus, adrenal and ovary weight. High dose animals showed elevated brain, heart, kidney, and liver weight, relative to bodyweight. Adrenal and epididymis weight, relative to bodyweight was reduced for high dose males. No such effects were observed in animals treated with 50 or 5 mg/kg/day.
Treatment-related effects in organs included:
Liver: Hepatotoxicity was observed in high dose animals; morphological changes included generalised hepatocyte enlargement, single cell hepatocyte necrosis, karyomegaly and variation in nuclear size, increased mitotic activity, bile duct proliferation, eosinophilic inclusions and accumulations of pigment. These changes were seen more frequently in prematurely dead animals.
Spleen: Higher grades of severity of pigment accumulation were seen in relation to treatment in high dose males only.
Adrenals: Treatment-related cortical atrophy was seen for all males and several females in high dose groups.
Kidneys: Tubular basophilia, tubular degeneration and accumulations of eosinophilic pigment were observed in high dose animals.
Lungs: A higher incidence of accumulations of alveolar macrophages was seen in high dose animals.
Lymph Nodes: Vacuolated histiocytes were seen in the lymph nodes of high dose animals. Cervical and mesenteric nodes were affected but changes were more severe and prevalent in mesenteric nodes.
Reproductive organs: Bilateral testicular atrophy of a varying degree of severity was seen in high dose males, as was a reduction in spermatozoal content. reduced sectretory content of the prostate and seminal vesicles was also observed in high dose males. The ovaries of three high dose females contained no developing follicles.
No such effects as described above were observed for animals of either sex treated with 50 or 5 mg/kg/day.
Necropsy: Interim death animals displayed pale, red or small adrenals, dark contents present in the intestines and stomach, raised limiting ridge of the stomach, pale or mottled appearance of the liver and kidneys, and dark or pale lungs with multiple dark foci present. Pale kidneys and small darkened adrenals were detected for terminal kill high dose animals. Pale liver, gastro-intestinal tract, pituitary gland and uterus were also detected, together with small testes and seminal vesicles for individual males, and small ovaries detected for one female. No treatment-related macroscopic abnormalities were detected for animals treated with 50 or 5 mg/kg/day at terminal kill
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 50 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
- Dose descriptor:
- NOEL
- Effect level:
- 50 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Clinical signs:Clinically observable signs of hunched posture was detected for 750 mg/kg/day females from Day 18, and 750 mg/kg/day males from Day 21. Deterioration in physical condition was evident for interim death females, displaying signs such as hunched posture, pilo-erection, pallor of the extremities and tiptoe gait, prior to death on Days 28, 42 and Day 53. Due to the number of deaths detected at this dose level, the high level was reduced to 500 mg/kg/day from Day 56 onwards for all high dose animals. The reduction in dose level did not result in a regression in clinical signs, and pallor of the extremities was evident for all high dose animals until the end of the study, with hunched posture also detected for individual animals.
Bright yellow staining was also detected on cage tray-liners of high dose females. Deteriorating physical condition resulted in deaths of two further females on Days 58 and 74, and two males on Days 85 and 89. No treatment-related clinical observations were detected for animals of either sex treated with 50 or 5 mg/kg/day.
Behavioural Assessment. Weekly open field arena observations confirmed the clinical signs of hunched posture, tiptoe gait and pallor of the extremities detected for high dose animals during the study. No treatment-related effects were detected for animals of either sex treated with 50 or 5 mg/kg/day.
Functional Performance Tests. No treatment-related changes were detected.
Sensory Reactivity Assessments. Elevated startle reflex responses were detected for high dose animals of either sex. No such effects were detected for animals of either sex treated with 50 or 5 mg/kg/day.
Organ Weights. High dose males showed a reduction in absolute weight for the majority of the organs, whereas high dose females showed reduced absolute spleen, thymus, adrenal and ovary weight. Animals of either sex treated at the high dose level showed elevated brain, heart, kidney and liver weight, relative to bodyweight. Adrenal and epididymis weight, relative to bodyweight
was reduced for high dose males. No such effects were detected for animals of either sex treated with 50 or 5 mg/kg/day.
Gross pathology: Interim death animals displayed pale, red or small adrenals, dark contents present in the intestines and stomach, raised limiting ridge of the stomach, pale or mottled appearance of the liver and kidneys, and dark or pale lungs with multiple dark foci present. Isolated cases of a pale pancreas/uterus, and small testesfseminal vesicles were also evident. One female was cannibalised, with most of the major organs not present at necropsy. Pale kidneys and small darkened adrenals were detected for terminal kill high dose animals of either sex. Pale liver, gastro-intestinal tract, pituitary gland and uterus were also detected, together with small testes and seminal vesicles for individual males, and small ovaries detected for one female. No treatmentrelated macroscopic abnormalities were detected for animal treated with 50 or 5 mg/kg/day at terminal kill.
Histopathology. The following treatment-related changes were observed:
LIVER: Hepatotoxicity was observed in animals of either sex treated at the high dose. Morphological changes included generalised hepatocyte enlargement, single cell hepatocyte necrosis, karyomegaly and variation in nuclear size, increased mitotic activity, bile duct
proliferation, eosinophilic inclusions and accumulations of pigment. These changes were seen more frequently in, but not restricted to, premature death animals. In addition, some animals dying or killed before scheduled termination, demonstrated periportal hepatocyte vacuolation consistent with lipid accumulation. Two premature death females were also observed to have multifocal hepatocyte necrosis and one premature death male demonstrated periportal hepatocyte degeneration/necrosis. No such effects were detected for animals of either sex treated with 50 or 5 mg/kg/day.
SPLEEN: Higher grades of severity of pigment accumulation were seen in relation to treatment for high dose males. A similar effect was not observed for high dose females, or for animals of either sex treated with 50 or 5 mg/kg/day.
HEART: Vacuolation of groups of interstitial cells was observed in the myocardium of a few animals, predominantly for premature death animals, of either sex treated with the high dose only.
PANCREAS: An oedematous appearance of the exocrine pancreas was observed in relation to treatment for a few animals, predominantly for premature death animals treated with the high dose only.
ADRENALS: Treatment-related cortical atrophy was seen for all males and several females treated with the high dose only.
KIDNEYS: Tubular basophilia, tubular degeneration and accumulations of eosinophilic pigment were observed in relation to treatment for animals of either sex treated with the high dose only.
LUNGS: A higher incidence of accumulations of alveolar macrophages was seen in relation to treatment for high dose animals of either sex. No such effects were detected at the 50 or 5 mg/kg/day dose level.
LYMPH NODES: Vacuolated histiocytes were seen as a consequence of treatment in the lymph nodes of animals of either sex treated with the high dose. Cervical and mesenteric nodes were affected but changes were more severe and more prevalent in mesenteric nodes.
THYMUS: Lymphoid atrophy was seen in relation to treatment for all high dose, premature death male or female animals for which the tissue was available.
BONE (Femur): Trabecular bone formation was generally more pronounced for male animals and possibly also for females treated with the high dose only.
BONE MARROW (Sternum): Adipose infiltration of the marrow was observed with generally higher grades of severity in male animals treated with the high dose. Such is indicative of marginal marrow hypoplasia. Female animals at this dose level were not similarly affected. No such effects were observed for animals of either sex treated with 50 or 5 mg/kg/day.
TESTES: Bilateral testicular atrophy of a varying degree of severity was seen for all male animals treated with the high dose, but not at any other dose level.
EPIDIDYMIDES: A reduction in spermatozoa1 content was observed in relation to treatment for all male animals treated with the high dose only.
PROSTATE: Reduced secretory content was seen in relation to treatment for male animals treated with the high dose only.
SEMINAL VESICLES: A treatment-related reduction in secretory content was seen for all male animals treated with the high dose only.
OVARIES: The ovaries of three females, one of which died before scheduled termination, contained no developing follicles.
Applicant's summary and conclusion
- Conclusions:
- Oral administration of the test material to rats, by gavage, for a period of ninety consecutive days at dose levels of up to 750 mg/kg/day (reduced to 500 mg/kg/day from Day 56) resulted in treatment-related changes at the highest dose level.
No effects were demonstrated in animals treated with 50 or 5 mg/kg/day and the "No Observed Effect Level" (NOEL) was, therefore, considered to be 50 mg/kg/day. - Executive summary:
Toxicity was characterised mainly by unspecific signs of ill health in the high dose group (reduced body weight, food consumption, clinical signs, weights of several organs)
Target organs identified by microscopy in the high dose group only were: Kidney, liver, blood, spleen, adrenals, lungs, lymph nodes, reproductive organs (testes, prostate and seminal vesicles, ovaries).
No such effects as described above were observed for animals of either sex treated with 50 or 5 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies